{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:31:26Z","timestamp":1786977086743,"version":"build-2736575974"},"reference-count":46,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T00:00:00Z","timestamp":1301443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the safety and efficacy of abatacept, a selective T cell costimulation modulator, in patients with psoriatic arthritis (PsA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this 6\u2010month, multicenter, randomized, double\u2010blind, placebo\u2010controlled, phase II study, 170 PsA patients with a psoriasis target lesion (TL) \u22652 cm who had previously taken disease\u2010modifying antirheumatic drugs (DMARDs), including anti\u2013tumor necrosis factor (anti\u2010TNF) agents, were randomized (1:1:1:1) to receive placebo or abatacept at doses of 3 mg\/kg, 10 mg\/kg, or 30\/10 mg\/kg (2 initial doses of 30 mg\/kg, followed by 10 mg\/kg) on days 1, 15, and 29 and then once every 28 days thereafter. The primary end point was the American College of Rheumatology 20% criteria for improvement (ACR20 response) on day 169. Other key end points were magnetic resonance imaging (MRI) scores for joint erosion, osteitis, and synovitis, scores on the Health Assessment Questionnaire (HAQ) and the Short Form\u201036 (SF\u201036) health survey, the investigator's global assessment of psoriasis, the TL score, and the Psoriasis Area and Severity Index (PASI) score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Proportions of patients achieving an ACR20 response were 19%, 33%, 48%, and 42% in the placebo, the abatacept 3 mg\/kg, the abatacept 10 mg\/kg, and the abatacept 30\/10 mg\/kg groups, respectively. Compared with placebo, improvements were significantly higher for the abatacept 10 mg\/kg (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.006) and 30\/10 mg\/kg (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.022) groups, but not for 3 mg\/kg group (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.121). All abatacept regimens resulted in improved MRI, HAQ, and SF\u201036 scores, with 10 mg\/kg showing the greatest improvements. Improvements in the TL and PASI scores were observed in all abatacept arms; a response according to the investigator's global assessment was seen only with 3 mg\/kg of abatacept. The safety profiles were similar among the treatment arms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results of this study suggest that 10 mg\/kg of abatacept, the approved dosage for rheumatoid arthritis and juvenile idiopathic arthritis, may be an effective treatment option for PsA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.30176","type":"journal-article","created":{"date-parts":[[2010,12,2]],"date-time":"2010-12-02T12:02:29Z","timestamp":1291291349000},"page":"939-948","source":"Crossref","is-referenced-by-count":250,"title":["Abatacept in the treatment of patients with psoriatic arthritis: Results of a six\u2010month, multicenter, randomized, double\u2010blind, placebo\u2010controlled, phase II trial"],"prefix":"10.1002","volume":"63","author":[{"given":"Philip","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Gladstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Kivitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul P.","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wollenhaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orna","family":"Bahary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Claude","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Sigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,30]]},"reference":[{"key":"e_1_2_8_2_2","first-page":"127","article-title":"Psoriatic arthritis (PSA)\u2014an analysis of 220 patients","volume":"62","author":"Gladman DD","year":"1987","journal-title":"Q J Med"},{"key":"e_1_2_8_3_2","first-page":"809","article-title":"Longitudinal study of clinical and radiological progression in psoriatic arthritis","volume":"17","author":"Gladman DD","year":"1990","journal-title":"J Rheumatol"},{"key":"e_1_2_8_4_2","first-page":"1247","article-title":"The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982\u20101991","volume":"27","author":"Shbeeb M","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.03.046"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03159.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.09023.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094946"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"e_1_2_8_12_2","first-page":"869","article-title":"Two\u2010year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"35","author":"Antoni CE","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22379"},{"key":"e_1_2_8_15_2","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese MC","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092767"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-007-0071-5"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.050963"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10543"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21870"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.09.050"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091389"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00780.x"},{"key":"e_1_2_8_25_2","first-page":"2162","article-title":"Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis","volume":"33","author":"Weisman MH","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050524"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.085084"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-12-200606200-00003"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.074773"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21201"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60998-8"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI5857"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.5.681"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_8_36_2","first-page":"789","article-title":"The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales","volume":"9","author":"Fries JF","year":"1982","journal-title":"J Rheumatol"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107263450403"},{"issue":"1","key":"e_1_2_8_39_2","first-page":"i39","article-title":"How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines","volume":"63","author":"Mease P","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_2_8_41_2","first-page":"859","article-title":"Developing a magnetic resonance imaging scoring system for peripheral psoriatic arthritis","volume":"34","author":"McQueen F","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_8_42_2","first-page":"1385","article-title":"OMERACT rheumatoid arthritis magnetic resonance imaging studies: core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA\u2010MRI scoring system","volume":"30","author":"Ostergaard M","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199915020-00003"},{"key":"e_1_2_8_44_2","first-page":"38","article-title":"Joint damage in psoriatic arthritis: how is it assessed and can it be prevented?","volume":"4","author":"Mease PJ","year":"2006","journal-title":"Int J Adv Rheumatol"},{"key":"e_1_2_8_45_2","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept","volume":"33","author":"Mease PJ","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.100149"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10683"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.30176","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.30176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T03:47:21Z","timestamp":1700711241000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.30176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,30]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1002\/art.30176"],"URL":"https:\/\/doi.org\/10.1002\/art.30176","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,30]]}}}